Skip to content Skip to footer

Atavistik Bio Inks ~$1.97B Partnership with Roche to Advance Allosteric Small Molecules for CVRM Diseases

Shots: Atavistik Bio has entered into a strategic research collaboration with Roche to discover & develop novel small molecules against multiple targets for cardiovascular, renal, and metabolic (CVRM) diseases, using Atavistik’s AMPS platform As per the deal, Atavistik Bio will be responsible for discovery & research activities for the collaboration targets, with Roche responsible for…

Read more

Atavistik Bio Partners with Pfizer to Discover Novel Precision Allosteric Therapeutics

Shots: Atavistik Bio has signed a research collaboration with Pfizer to discover novel precision allosteric therapies for significant unmet medical needs As per the terms, Atavistik Bio will identify allosteric binders for Pfizer’s 2 undisclosed targets, with Pfizer having the option to license the programs post research. Financial terms are undisclosed The alliance…

Read more